American Journal of Roentgenology, Vol 156, 561-565, Copyright © 1991 by American Roentgen Ray Society

ARTICLES

Deferoxamine-induced bone dysplasia in patients with thalassemia major

PW Brill, P Winchester, PJ Giardina and S Cunningham-Rundles
Department of Radiology, New York Hospital-Cornell Medical Center, NY 10021.

Metaphyseal irregularity and abnormal vertebral bodies resembling a bone dysplasia were seen in two of five children with thalassemia major who were begun on a regimen of hypertransfusion and chelation with deferoxamine before the age of 3 years. Similar changes were not seen in 22 other children in whom chelation was started after the age of 3. Whether the dysplastic bone growth was related to drug dose or age of onset of chelation could not be determined, as deferoxamine dosages differed in the two groups. Findings on radiographs included flattening of the thoracic and lumbar vertebral bodies, circumferential metaphyseal osseous defects, sharp zones of provisional calcification, and widened growth plates. Healing was noted in one of the patients after the dose of deferoxamine was decreased. Zinc levels in both affected patients did not differ from those in the 25 other chelated patients.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				C. J. Kellenberger, M. Schmugge, T. Saurenmann, L. D. Gennaro, S. W. Eber, U. V. Willi, and P. S. Babyn Radiographic and MRI Features of Deferiprone-Related Arthropathy of the Knees in Patients with {beta}-Thalassemia Am. J. Roentgenol., October 1, 2004; 183(4): 989 - 994. [Abstract] [Full Text] [PDF]

				M A Hall-Craggs, J Porter, P D Gatehouse, and G M Bydder Ultrashort echo time (UTE) MRI of the spine in thalassaemia Br. J. Radiol., February 1, 2004; 77(914): 104 - 110. [Abstract] [Full Text] [PDF]

				R. J. Bergeron, J. Wiegand, and G. M. Brittenham HBED ligand: preclinical studies of a potential alternative to deferoxamine for treatment of chronic iron overload and acute iron poisoning Blood, April 15, 2002; 99(8): 3019 - 3026. [Abstract] [Full Text] [PDF]

				Y.-l. Chan, C.-k. Li, W. C.-w. Chu, L.-m. Pang, J. C.-y. Cheng, and K.-W. Chik Deferoxamine-Induced Bone Dysplasia in the Distal Femur and Patella of Pediatric Patients and Young Adults: MR Imaging Appearance Am. J. Roentgenol., December 1, 2000; 175(6): 1561 - 1566. [Abstract] [Full Text] [PDF]

				R. J. Bergeron, J. Wiegand, and G. M. Brittenham HBED: The Continuing Development of a Potential Alternative to Deferoxamine for Iron-Chelating Therapy Blood, January 1, 1999; 93(1): 370 - 375. [Abstract] [Full Text] [PDF]

				N. F. Olivieri and G. M. Brittenham Iron-Chelating Therapy and the Treatment of Thalassemia Blood, February 1, 1997; 89(3): 739 - 761. [Full Text] [PDF]